921.40
-0.83%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aarti Pharmalabs
Its shares trade on NSE under the ticker AARTIPHARM.NS. It has been listed since 30 January 2023. In the fiscal year to 31 March 2026, it reported revenue of ₹18.19bn and net income of ₹1.75bn. At that date it held total assets of ₹34.82bn and shareholders' equity of ₹21.25bn.
Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Jan 2023
- Employees
- 1,400
- Website
- aartipharmalabs.com ↗
Leadership
Pay as last reported
- Shri. Rashesh GogriChairman of the Board, since 2021
- Dr. Rakeshwar BandichhorChief Scientific Officer - Research and Development
- Mr. Jeevan MondkarCompany Secretary and Compliance Officer
- Smt. Hetal GalaDirector
- Mr. Chetan GandhiDirector
- Mr. Rajendra GogriDirector
- Shri. Narendra SalviDirector
- Smt. Nehal GarewalNon-Executive Non-Independent Director
- Shri. Pradeep ThakurNon-Executive Independent Director
- Ms. Rupal VoraNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aarti Pharmalabs Ltd employs 1400 full-time staff members in Mumbai.
- The company manufactures specialized corticosteroids and cytotoxic medicines for global clients.
- Ramipril and Apixaban are key API products in their pharmaceutical portfolio.
Weaknesses
- The firm went public on 30 January 2023 with a recent listing date.
- Headquarters are located in Mumbai, Maharashtra, which may limit local reach.
- Only 1400 employees are available to support extensive CDMO operations.
Opportunities
- Growing demand for drug substance development supports their CDMO service expansion.
- Oncology products like Abemaciclib Intermediate offer new revenue streams for growth.
- Nutraceutical product sales can diversify income beyond traditional pharmaceutical manufacturing.
Threats
- Intense competition in the global pharmaceutical API market poses pricing risks.
- Regulatory changes in India could impact manufacturing costs and timelines.
- Supply chain disruptions may affect the production of critical intermediates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.